Intrommune Therapeutics

Intrommune Therapeutics

Early Stage

Safe And Effective Food Allergy Therapies

Safe And Effective Food Allergy Therapies

Overview

Raised to Date: Raised: $0

Logos provided by Clearbit
Platform

Self Managed

Start Date

06/21/2021

Close Date

07/07/2021

Min. Goal
$1,000
Max. Goal
$20,000,000
Min. Investment

$1,000

Security Type

Equity - Common

SEC Filing Type

RegD 506(c)    Open SEC Filing

Logos provided by Clearbit
Status
Funded
Reporting Date

07/30/2021

Days Remaining
Funded
% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise

$0

Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Logos provided by Clearbit
Year Founded

2013

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Location

New York, New York

Company Website

Intrommune Therapeutics is raising funds independently through Reg D 506(c) crowdfunding. The company is developing safe and effective food allergy therapies through its novel drug delivery platform. The technology is embedding therapeutic agents in a fully-functional toothpaste for convenient administration as a daily treatment. The allergy immunotherapy used by Intrommune Therapeutics is termed oral mucosal immunotherapy and delivers allergenic proteins to individuals. Michael Nelson and Erick Berglund founded Intrommune Therapeutics in 2013. The current crowdfunding campaign has a minimum target of $1,000 and a maximum target of $20,000,000. The campaign proceeds will be used for growth and expansion.
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Intrommune Therapeutics 07/06/2021 Self Managed - $0 Equity - Common Funded RegD 506(c)
Intrommune Therapeutics 06/28/2018 Netcapital $15,000,000 $157,806 Equity - Common Funded RegCF / RegD 506(c)
Create a free account today to gain access to KingsCrowd analytics.

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Funding data not publicly available

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Intrommune Therapeutics on Self Managed 2021
Platform: Self Managed
Security Type: Equity - Common

Follow company

Follow Intrommune Therapeutics on Self Managed 2021
Deal Analytics
Deal Considerations

Buy Intrommune Therapeutics's Deal Report

Warning: according to the close date for this deal, Intrommune Therapeutics may no longer be accepting investments.

Intrommune Therapeutics Deal Report

Get KingsCrowd’s comprehensive report on Intrommune Therapeutics including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Intrommune Therapeutics is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Intrommune Therapeutics deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge